FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099169909> ?p ?o ?g. }

• W2099169909 endingPage "1307.e5" @default.
• W2099169909 startingPage "1296" @default.
• W2099169909 abstract "We analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and ACT-2) to assess relationships between serum concentrations of infliximab and outcomes of adults with moderate-to-severe ulcerative colitis.We compared serum concentrations of infliximab with outcomes of 728 patients with moderately-to-severely active ulcerative colitis who participated in ACT-1 or ACT-2; efficacy data were collected at weeks 8, 30, and 54 (for ACT-1 only). Relationships between serum concentration of infliximab and efficacy outcomes were assessed using trend, logistic regression, and receiver operating characteristic curve analyses. We also evaluated factors that affected the relationship between exposure and response.Median serum concentrations of infliximab at weeks 8, 30, and/or 54 were significantly higher in patients with clinical response, mucosal healing, and/or clinical remission than in patients who did not meet these response criteria. There were statistically significant relationships between quartile of infliximab serum concentration and efficacy at these time points (P < .01). Infliximab therapy was effective for a smaller proportion of patients in the lowest quartile, and these patients had lower serum levels of albumin and a higher incidence of antibodies to infliximab than patients in other quartiles. Although the relationship between exposure to infliximab and response varied among patients, approximate serum concentrations of 41 μg/mL infliximab at week 8 of induction therapy and 3.7 μg/mL at steady-state during maintenance therapy produced optimal outcomes in patients.Serum concentrations of infliximab are associated with efficacy in patients with moderate-to-severe ulcerative colitis; however, complex factors determine the relationship between exposure to this drug and response. A prospective evaluation of the value of measuring serum concentrations of infliximab should be performed before these data can be included in patient management strategies. Clinicaltrials.gov numbers: NCT00036439 and NCT00096655." @default.
• W2099169909 created "2016-06-24" @default.
• W2099169909 creator A5006410526 @default.
• W2099169909 creator A5013058329 @default.
• W2099169909 creator A5031629161 @default.
• W2099169909 creator A5045988031 @default.
• W2099169909 creator A5048464948 @default.
• W2099169909 creator A5052046238 @default.
• W2099169909 creator A5052113690 @default.
• W2099169909 creator A5061609589 @default.
• W2099169909 creator A5070461768 @default.
• W2099169909 creator A5076610847 @default.
• W2099169909 creator A5083726032 @default.
• W2099169909 date "2014-12-01" @default.
• W2099169909 modified "2023-10-14" @default.
• W2099169909 title "Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis" @default.
• W2099169909 cites W1968331553 @default.
• W2099169909 cites W1997999969 @default.
• W2099169909 cites W2001929304 @default.
• W2099169909 cites W2003904406 @default.
• W2099169909 cites W2020640954 @default.
• W2099169909 cites W2038457542 @default.
• W2099169909 cites W2040157712 @default.
• W2099169909 cites W2043261411 @default.
• W2099169909 cites W2044160586 @default.
• W2099169909 cites W2045859764 @default.
• W2099169909 cites W2050154180 @default.
• W2099169909 cites W2063138494 @default.
• W2099169909 cites W2087663450 @default.
• W2099169909 cites W2088135039 @default.
• W2099169909 cites W2095161324 @default.
• W2099169909 cites W2101051493 @default.
• W2099169909 cites W2102245241 @default.
• W2099169909 cites W2103755206 @default.
• W2099169909 cites W2117212747 @default.
• W2099169909 cites W2118088660 @default.
• W2099169909 cites W2118559127 @default.
• W2099169909 cites W2145573746 @default.
• W2099169909 cites W2146963207 @default.
• W2099169909 cites W2152575748 @default.
• W2099169909 cites W2170364552 @default.
• W2099169909 cites W2171297959 @default.
• W2099169909 cites W2321205867 @default.
• W2099169909 doi "https://doi.org/10.1053/j.gastro.2014.08.035" @default.
• W2099169909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25173754" @default.
• W2099169909 hasPublicationYear "2014" @default.
• W2099169909 type Work @default.
• W2099169909 sameAs 2099169909 @default.
• W2099169909 citedByCount "276" @default.
• W2099169909 countsByYear W20991699092014 @default.
• W2099169909 countsByYear W20991699092015 @default.
• W2099169909 countsByYear W20991699092016 @default.
• W2099169909 countsByYear W20991699092017 @default.
• W2099169909 countsByYear W20991699092018 @default.
• W2099169909 countsByYear W20991699092019 @default.
• W2099169909 countsByYear W20991699092020 @default.
• W2099169909 countsByYear W20991699092021 @default.
• W2099169909 countsByYear W20991699092022 @default.
• W2099169909 countsByYear W20991699092023 @default.
• W2099169909 crossrefType "journal-article" @default.
• W2099169909 hasAuthorship W2099169909A5006410526 @default.
• W2099169909 hasAuthorship W2099169909A5013058329 @default.
• W2099169909 hasAuthorship W2099169909A5031629161 @default.
• W2099169909 hasAuthorship W2099169909A5045988031 @default.
• W2099169909 hasAuthorship W2099169909A5048464948 @default.
• W2099169909 hasAuthorship W2099169909A5052046238 @default.
• W2099169909 hasAuthorship W2099169909A5052113690 @default.
• W2099169909 hasAuthorship W2099169909A5061609589 @default.
• W2099169909 hasAuthorship W2099169909A5070461768 @default.
• W2099169909 hasAuthorship W2099169909A5076610847 @default.
• W2099169909 hasAuthorship W2099169909A5083726032 @default.
• W2099169909 hasBestOaLocation W20991699091 @default.
• W2099169909 hasConcept C126322002 @default.
• W2099169909 hasConcept C151956035 @default.
• W2099169909 hasConcept C17991360 @default.
• W2099169909 hasConcept C2775862500 @default.
• W2099169909 hasConcept C2777138892 @default.
• W2099169909 hasConcept C2779134260 @default.
• W2099169909 hasConcept C2780479503 @default.
• W2099169909 hasConcept C44249647 @default.
• W2099169909 hasConcept C68443243 @default.
• W2099169909 hasConcept C71924100 @default.
• W2099169909 hasConcept C90924648 @default.
• W2099169909 hasConceptScore W2099169909C126322002 @default.
• W2099169909 hasConceptScore W2099169909C151956035 @default.
• W2099169909 hasConceptScore W2099169909C17991360 @default.
• W2099169909 hasConceptScore W2099169909C2775862500 @default.
• W2099169909 hasConceptScore W2099169909C2777138892 @default.
• W2099169909 hasConceptScore W2099169909C2779134260 @default.
• W2099169909 hasConceptScore W2099169909C2780479503 @default.
• W2099169909 hasConceptScore W2099169909C44249647 @default.
• W2099169909 hasConceptScore W2099169909C68443243 @default.
• W2099169909 hasConceptScore W2099169909C71924100 @default.
• W2099169909 hasConceptScore W2099169909C90924648 @default.
• W2099169909 hasIssue "6" @default.
• W2099169909 hasLocation W20991699091 @default.
• W2099169909 hasLocation W20991699092 @default.
• W2099169909 hasOpenAccess W2099169909 @default.

• next